Skip to main content

Day: May 26, 2020

C-Bond Systems to Present at the June 2020 Virtual Investor Summit

HOUSTON, May 26, 2020 (GLOBE NEWSWIRE) — C-Bond Systems, Inc., (OTC: CBNT), a nanotechnology solutions company, today announced that management will present at the June 2020 Virtual Investor Summit on June 9-12, 2020.Scott R. Silverman, Chief Executive Officer of C-Bond Systems, will host virtual one-on-one investor meetings throughout the conference and is scheduled to present as follows:Virtual Investor Summit              Date: Tuesday, June 9, 2020       Time: 9:45 a.m. Eastern time (6:45 a.m. Pacific time)       Webcast:  https://www.webcaster4.com/Webcast/Page/2038/35029Conference participation is by invitation only and registration is mandatory. For more information, or to schedule a virtual one-on-one meeting, please contact your conference representative.About C-Bond   C-Bond Systems, Inc. (OTC: CBNT) is a Houston-based...

Continue reading

Sharps Compliance to Present at Stifel’s 2020 Virtual Cross Sector Insight Conference

HOUSTON, May 26, 2020 (GLOBE NEWSWIRE) — Sharps Compliance Corp. (Nasdaq: SMED) announced today that David P. Tusa, Chief Executive Officer will be presenting at the Stifel 2020 Virtual Cross Sector Conference on June 9, 2020 at 9:20 a.m. Eastern time.  Mr. Tusa will also be available throughout the day for one-on-one meetings via teleconference.About Sharps Compliance Corp.Headquartered in Houston, Texas, Sharps Compliance is a leading full-service national provider of comprehensive waste management services including medical, pharmaceutical and hazardous. Its key markets include healthcare facilities, pharmaceutical manufacturers, home healthcare providers, assisted living / long-term care, surgery centers, retail pharmacies and clinics, and the professional market which is comprised of physicians, dentists and veterinary practices....

Continue reading

CRISPR Therapeutics to Participate in Upcoming Investor Conferences

ZUG, Switzerland and CAMBRIDGE, Mass., May 26, 2020 (GLOBE NEWSWIRE) — CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team are scheduled to participate virtually in the following investor conferences in June:Jefferies Global Healthcare ConferenceDate: Tuesday, June 2, 2020Fireside chat: 1:30 p.m. ETGoldman Sachs 41st Annual Global Healthcare ConferenceDate: Tuesday, June 9, 2020Fireside chat: 9:40 a.m. ETA live webcast of these events will be available on the “Events & Presentations” page in the Investors section of the Company’s website at https://crisprtx.com/events. A replay of the webcast will be archived on the Company’s website for 14 days following...

Continue reading

Auris Medical Announces Positive Top-Line Data from AM-201 Phase 1b Study in Antipsychotic-Induced Weight Gain and Provides Update on TRAVERS Phase 2 Study

Administration of intranasal betahistine 30 mg shows statistically significant reduction in olanzapine-induced weight gainTreatment well tolerated and safe with no adverse effectsEnrollment into Phase 2 TRAVERS trial with AM-125 resumed following break due to COVID-19 pandemicHamilton, Bermuda, May 26, 2020 – Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology and central nervous system disorders, today announced positive top-line data from its Phase 1b trial with AM-201 in antipsychotic-induced weight gain and provided an update on the enrollment into its Phase 2 trial with AM-125 in vertigo.The Phase 1b trial demonstrated good safety and tolerability of ascending doses of AM-201 as well as a dose-dependent reduction in weight...

Continue reading

Workday Executives to Present Virtually at Three Upcoming Investor Conferences

PLEASANTON, Calif., May 26, 2020 (GLOBE NEWSWIRE) — Workday, Inc. (NASDAQ: WDAY), a leader in enterprise cloud applications for finance and human resources, today announced that it will have executives present virtually at three upcoming investor conferences. These include:Leighanne Levensaler, chief marketing officer, and executive vice president of corporate strategy, Workday, will present at the Morgan Stanley 2020 Cloud Secular Winners Virtual Conference on Monday, June 1, at 12:00 p.m. Pacific Time / 3:00 p.m. Eastern Time. Individuals may access the live webcast of the presentation here.Aneel Bhusri, co-founder and CEO, Workday, will present at the Bank of America Securities 2020 Global Technology Conference on Tuesday, June 2, at 11:30 a.m. Pacific Time / 2:30 p.m. Eastern Time. Individuals may access the live webcast of...

Continue reading

Veru to Present at Jefferies Virtual Healthcare Conference on June 2nd

MIAMI, May 26, 2020 (GLOBE NEWSWIRE) — Veru Inc. (NASDAQ: VERU), an oncology and urology biopharmaceutical company with a focus on developing novel medicines for the management of prostate cancer, today announced that the Company will present at the Jefferies Virtual Healthcare Conference on Tuesday, June 2, 2020 at 9:30 a.m. ET.A webcast of the presentation will be available at https://verupharma.com/investors. Listeners are encouraged to visit the website at least 10 minutes prior to the start of the scheduled presentation to register, download and install any necessary software. The webcast will be archived and accessible on the web site for at least 90 days.About Veru Inc.Veru Inc. is an oncology and urology biopharmaceutical company with a focus on developing novel medicines for the management of prostate cancer. The Veru prostate...

Continue reading

Majority of U.S. Businesses Say Pandemic Will Change Future Operations

NEW YORK, May 26, 2020 (GLOBE NEWSWIRE) — More than half (54 percent) of U.S. companies are likely to overhaul their long-term business strategies as a result of the COVID-19 pandemic, with 51 percent looking to invest in digital technologies, according to research conducted by Opinium and LiveArea, a customer experience and commerce agency, and business unit of PFSweb, Inc., (NASDAQ: PFSW).Key data findings from the LiveArea study include:43 percent of respondents are prioritizing investment in digital commerce41 percent of respondents are focusing on IT infrastructure investment to support the transition to digitalBusiness Agility34 percent of respondents are considering outsourcing IT activities33 percent of respondents are looking to outsource marketing activitiesThe May 2020 research also found the general economic downturn...

Continue reading

Delårsrapport for Dantax A/S for perioden 1. juli 2019 – 31. marts 2020

Delårsrapport for Dantax A/S for perioden 1. juli 2019 – 31. marts 2020Resume:Periodens resultat blev et underskud på 7,6 mio. kr. mod et overskud på 1,4 mio. kr. sidste år. Resultat af primær drift udgør et underskud på 0,4 mio. kr. og resultat af finansielle poster udgør et negativt resultat på 7,2 mio. kr. efter skat.   En del af selskabets overskydende likviditet er investeret i børsnoterede aktier. I perioden har der gennemsnitligt været investeret 50 mio. kr. Investeringen har i perioden givet et negativt afkast på 9,2 mio. kr. før skat, svarende til et afkast på -18,4%. Det negative resultat for perioden er primært en følge af Covid-19 pandemien. Efterspørgslen er faldet, og uroen på de finansielle markeder har medført det negative resultat af værdipapirbeholdningen.    Forventningerne til årets resultat fastholdes til et...

Continue reading

Outlook Therapeutics Announces $16.0 Million Private Placement to Advance the Development of ONS-5010 / LYTENAVA™ (bevacizumab-vikg)

Strategic investment at a premium enhances Company’s ongoing development activities of ONS-5010 / LYTENAVA™ (bevacizumab-vikg), an investigational ophthalmic formulation of bevacizumab to treat wet AMD, toward FDA approval Syntone and Outlook to form joint venture to develop and commercialize ONS-5010 / LYTENAVA™ (bevacizumab-vikg) in greater ChinaMONMOUTH JUNCTION, N.J., May 26, 2020 (GLOBE NEWSWIRE) — Outlook Therapeutics, Inc. (Nasdaq: OTLK) (the Company), a late clinical-stage biopharmaceutical company working to develop the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, today announced it has entered into a Stock Purchase Agreement with Syntone Ventures LLC for a private placement of $16.0 million of common stock at a price of $1.00 per share. In addition, Outlook Therapeutics entered...

Continue reading

Baltika’s Unaudited Financial Results, First Quarter of 2020

Baltika Group ended the first quarter with a net loss of 2,474 thousand euros. The loss for the same period last year was 1,442 thousand euros. The financial results of the first quarter were strongly affected by the weak March caused by the global COVID-19 pandemic. January and February results were in accordance with the company’s forecasts.In the first quarter, COVID-19 had the strongest impact on Baltika Group’s operations in Lithuania, where all stores were closed as of 16 March due to orders from the Lithuanian government, and all shopping centers in Estonia were closed by a government decision on 27 March. In Latvia, the shops were open part-time during the week and closed on weekends. Since the declaration of the state of emergency, Baltika Group has directed even more resources to the e-shop www.andmorefashion.com,...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.